XML 43 R21.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Income Taxes | 12 Months Ended
--- | ---
Dec. 31, 2023
Disclosure of income tax [Abstract] |
Income Taxes | Income Taxes The provision for income taxes recorded in the consolidated financial statements differs from the amount which would be obtained by applying the statutory income tax rate to the loss before income taxes as follows:
| 2023 |  | 2022 |  | 2021
Loss before income taxes | $ | (27,655) |  | $ | (24,751) |  | $ | (26,255)
Statutory Canadian corporate tax rate | 23.00% |  | 23.00% |  | 23.00%
Anticipated tax recovery | (6,361) |  | (5,693) |  | (6,039)
Difference in tax rates | 2,841 |  | 3,552 |  | 2,716
Share-based compensation expense | 441 |  | 547 |  | 880
Revaluation of tax balances | 2 |  | (338) |  | (552)
Impact of Barbados rate change | (9,088) |  | — |  | —
Other permanent differences | 325 |  | (368) |  | 45
Expiry of tax benefits | 3,382 |  | 1,614 |  | 1,661
Change in fair value of warrant derivative | (1,215) |  | 5 |  | (4)
Provision to offset deferred tax asset | 9,770 |  | 765 |  | 1,342
Current income taxes | $ | 97 |  | $ | 84 |  | $ | 49
At December 31, 2023, we have non-capital losses of $110,450 and $129,884 in Canada and Barbados, respectively (December 31, 2022 - $98,475 and $145,405, respectively). These losses are expected to expire between 2024 and 2043, if not utilized. At December 31, 2023, we have Canadian investment tax credits of $4,056 (December 31, 2022 - $4,368) that are expected to expire between 2024 and 2043, if not utilized. As well, we have unclaimed Canadian scientific research and experimental development expenditures available to reduce future years’ taxable income of $28,376 (December 31, 2022 - $27,663). We also have unclaimed U.S. credits for research activities available to reduce future years' taxable income of $1,232 (December 31, 2022 - $1,285) expiring between 2031 and 2043. We have not recorded the potential benefits of these tax pools in these consolidated financial statements. Deferred tax assets are recognized, to the extent that it is probable that taxable income will be available to utilize the deductible temporary differences. The components of our unrecognized deferred tax asset are as follows:
| 2023 |  | 2022 |  | 2021
Non-capital losses carried forward | $ | 37,174 |  |  | $ | 26,726 |  |  | $ | 25,158 |
Scientific research and experimental development | 7,742 |  |  | 7,648 |  |  | 7,705 |
Investment tax credits | 3,123 |  |  | 3,363 |  |  | 3,716 |
Property and equipment | 382 |  |  | 366 |  |  | 351 |
Share issue costs | 833 |  |  | 518 |  |  | 648 |
Net capital losses carried forward | 6 |  |  | 6 |  |  | 6 |
Unrecognized deferred tax asset | $ | 49,260 |  |  | $ | 38,627 |  |  | $ | 37,584 |
The Company currently files income tax returns in the various jurisdictions in which it operates. These tax returns are subject to periodic examinations in the normal course by the applicable tax authorities. Management is not aware of any material income tax examinations currently in progress by any taxing jurisdiction.

X
- Definition The entire disclosure for income taxes. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 12 -IssueDate 2023-01-01 -Section Disclosure -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI -URIDate 2023-03-23 + Details
Name: | ifrs-full_DisclosureOfIncomeTaxExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Disclosure of income tax [Abstract] + References No definition available. + Details
Name: | oncyf_DisclosureofincometaxAbstract
Namespace Prefix: | oncyf_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration